To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT ID: NCT06552520
Last Updated: 2024-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
500 participants
INTERVENTIONAL
2024-09-30
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT05970432
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
NCT05409326
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
NCT07175233
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07054736
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
NCT06931990
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQH2722 injection
TQH2722 injection, 14 days for a treatment cycle
TQH2722 injection
Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
Placebo of TQH2722 injection
Placebo of TQH2722 injection, 14 days for a treatment cycle
Placebo of TQH2722 injection
Placebo without drug substance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQH2722 injection
Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
Placebo of TQH2722 injection
Placebo without drug substance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet the 2014 American Academy of Dermatology (AAD) standards, diagnosed as AD.
* During screening and baseline visit, eczema area and severity score (EASI) ≥16 points; Investigator global score (IGA) ≥3 points; Affected body surface area (BSA) ≥10%; Baseline pruritus Peak Value Scale (NRS) weekly mean ≥4 points.
* Have received at least 4 weeks of strong action or at least 2 weeks of super effective external glucocorticoid (TCS) treatment or sufficient duration of systemic glucocorticoid treatment, the efficacy is not sufficient; Or subjects cannot receive the above treatment due to adverse reactions or potential risks.
Exclusion Criteria
* Received topical calcineurin inhibitors (TCS), topical calcineurin inhibitors (TCI), and other topical preparations within 2 weeks before randomization.
* Received anti-interleukin-4 receptor alpha (IL-4R) monoclonal antibodies, anti-ige monoclonal antibodies, or other biologic agents within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.
* Had received live attenuated vaccine within 12 weeks prior to randomization or planned to receive it during the study period.
* Use of antihistamines within 1 week prior to randomization (unless you have received steady doses of antihistamines for at least 7 days).
* Received allergen specific immunotherapy within 6 months before randomization.
* There are skin comorbidities that may interfere with study evaluation.
* There is a history of clinically significant illness that the investigator believes poses a risk to the safety of the subject and is poorly controlled.
* A known or suspected history of immunosuppression (immune deficiency).
* Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and papillary thyroid carcinoma that have been cured for more than 5 years prior to the screening period).
* Subject may have active Mycobacterium tuberculosis infection.
* Subjects with severe liver and kidney function impairment.
* Screening period HIV antibody positive, or have a history of HIV infection.
* Screening period of treponema pallidum antibody positive.
* Participated in clinical trials of other drugs or medical devices within 12 weeks prior to randomization.
* Treatment-requiring infections were present in the 4 weeks prior to randomization.
* During the study period, subjects plan to undergo major surgical operations.
* Pregnant or lactating women.
* Alcohol, drug abuse and known drug dependence.
* History of atopic keratoconjunctivitis with corneal involvement.
* The subject has any medical or psychiatric symptoms that interfere with participation in the study or with the interpretation of the study results.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Tongling People's Hospital
Tongling, Anhui, China
The Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Chongqing Three Gorges Medical College affiliated People's Hospital
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, Fujian, China
Dermatology Hospital of Southern Medical UniversityDermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Liuzhou People's Hospital
Liuzhou, Guangxi, China
Cangzhou Central Hospital
Cangzhou, Hebei, China
The Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China
Heilongjiang Provincial Hospital
Harbin, Heilongjiang, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Qiqihar Hospital of Traditional Chinese Medicine
Qiqihar, Heilongjiang, China
Anyang District Hospital, Puyang City
Anyang, Henan, China
The Second Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Nanyang city first People's Hospital
Nanyang, Henan, China
Sanmenxia Central Hospital
Sanmenxia, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
Zhengzhou, Henan, China
Jingzhou Central Hospital
Jingzhou, Hubei, China
Wuhan University People's Hospital
Wuhan, Hubei, China
Yichang Central People's Hospital
Yichang, Hubei, China
The Second Xiangya Hospital, Central South University
Changsha, Hunan, China
Xiangya Third Hospital, Central South University
Changsha, Hunan, China
The First Affiliated Hospital of University of South China
Hengyang, Hunan, China
Hunan Medical University General Hospital
Huaihua, Hunan, China
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
Baotou, Inner Mongolia, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Changzhou First People's Hospital
Changzhou, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Yancheng First People's Hospital
Yancheng, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Second Hospital of Jilin University
Changchun, Jilin, China
Panjin Liao oil precious stone flower hospital
Panjin, Liaoning, China
Yinchuan First People's Hospital
Yinchuan, Ningxia, China
Affiliated Hospital of Qinghai University
Xining, Qinghai, China
Dezhou People's Hospital
Dezhou, Shandong, China
Shandong University Qilu Hospital
Jinan, Shandong, China
Liaocheng People's Hospital
Liaocheng, Shandong, China
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, China
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China
Baoji Central Hospital
Baoji, Shanxi, China
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Peking University First Hospital Taiyuan Hospital
Taiyuan, Shanxi, China
The Second Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China
The First Affiliated Hospital of PLA Air Force Medical University
Xi’an, Shanxi, China
The First Affiliated Hospital of Xi 'an Medical College
Xi’an, Shanxi, China
The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University
Xi’an, Shanxi, China
Chengdu Second People's Hospital
Chengdu, Sichuan, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Chengdu Second People's Hospital
Chengdu, Sichuan, China
Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Suining Central Hospital
Suining, Sichuan, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin, Tianjin Municipality, China
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Ürümqi, Xinjiang, China
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
Jiaxing second Hospital
Jiaxing, Zhejiang, China
Jinhua Central Hospital
Jinhua, Zhejiang, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQH2722-III-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.